Full Breakdown
Hims & Hers Launches Multi-Cancer Early Detection Test
2/6/2026, 1:51:49 AM
Introduction of the Galleri Test
Hims & Hers Health, Inc. has launched access to the Galleri® multi-cancer early detection (MCED) test, developed by GRAIL, Inc. This innovative blood test screens for signals associated with over 50 types of cancer, including those lacking standard screening protocols. The test aims to detect cancer signals before symptoms arise, thereby increasing the likelihood of early treatment and better outcomes. Hims & Hers is offering this test at a discounted price of $699, down from the list price of $949, to customers enrolled in their Labs plans.
Technology and Usage Guidelines
The Galleri test utilizes advanced technology to identify chemical changes in cell-free DNA (cfDNA) released by tumors into the bloodstream. It is particularly recommended for adults aged 50 and older or those at elevated risk for cancer. However, it is important to note that the test does not detect all cancers and may yield false positive or false negative results. It is intended to complement, not replace, routine cancer screenings recommended by healthcare providers. Results must be interpreted in conjunction with a patient’s medical history and further diagnostic evaluations are necessary to confirm any detected cancer signals.
Strategic Shift and Market Reaction
This launch marks a significant strategic pivot for Hims & Hers, expanding beyond its core prescription services into preventive diagnostics. The company reported a revenue increase of 49.2% year-over-year for Q3 2025, totaling approximately $599 million. Despite this growth, the initial market reaction to the launch was mixed, with Hims & Hers shares closing lower on the day of the announcement. Analysts are assessing whether this new offering will integrate effectively with the existing business model and drive measurable growth.
Official Statements & Responses
Andrew Dudum, CEO of Hims & Hers, emphasized the importance of access to innovative healthcare solutions, stating, “Access to innovation is the key to changing that. Our platform brings together the best the healthcare industry has to offer in order to close the access gap.” Josh Ofman, President at GRAIL, echoed this sentiment, highlighting the partnership's potential to enhance cancer detection and improve patient outcomes.
Criticism & Opposition
While the Galleri test represents a promising advancement in cancer screening, some experts caution against over-reliance on its results. The test is not FDA-approved, and its effectiveness and reliability are still under scrutiny. Critics argue that without comprehensive validation, the test could lead to unnecessary anxiety or medical procedures for patients receiving false positive results.
What's Next
Hims & Hers is expected to release its next quarterly earnings report on February 23, 2026, which will provide further insights into the financial impact of the Galleri test and the company's overall performance. As the partnership with GRAIL develops, stakeholders will be closely monitoring how this new offering influences Hims & Hers' market position and growth trajectory.
Verbatim Quotes
“Even though cancer screening technology has advanced significantly, there are still too many life-changing diagnoses that should have been made earlier.” — Andrew Dudum, CEO, Hims & Hers
“Hims & Hers is at the forefront of making healthcare more attainable and impactful for those who want to take control of their health,” — Josh Ofman, MD, MSHS, President, GRAIL
“With access to this new, innovative screening technology, we’re empowering customers to tackle health challenges when treatment can be more manageable and more successful.” — Dr. Pat Carroll, Chief Medical Officer, Hims & Hers
